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Abstract 
 
Fatigue is common and the debilitating symptom in patients with rheumatoid arthritis (RA). 
Since 2007, fatigue has been included as one of the core outcome measures in RA. Clinical 
trials of biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic 
disease modifying antirheumatic drugs (tsDMARDs) have included fatigue as a secondary 
endpoint. A Cochrane review in 2016 concluded that the bDMARDs have a moderate effect 
on improving fatigue in RA. More recent clinical trials of the new biological agents Sarilumab 
and the Janus Kinase inhibitors, Tofacitinib and Baricitinib showed similar benefits. It 
remains unclear whether the effect of bDMARDs and tsDMARDs on fatigue is mediated by 
direct effects or through reduction in inflammation. As fatigue was a secondary endpoint, 
many analyses did not adjust for potential confounding factors including pain, mood and 
anaemia which is a significant limitation. 
 
Key messages: 
1. Biologic DMARDs reduce fatigue in patients with RA. 
2. Janus kinases inhibitors, Tofacitinib and Baricitinib reduce fatigue in patients with RA. 
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Background 
Rheumatoid arthritis (RA) is a chronic inflammatory arthritis associated with increased 
mortality and morbidities. Joint inflammation and destruction are the dominant clinic 
features and standard of care focussed on “treat-to-target” based on suppressing joint 
inflammation to a minimal level either remission or failing this, low disease activity1. From 
the patients’ perspective, the dominant symptoms in RA are pain and fatigue2,3. Fatigue is 
common in RA patients affecting over 80% of patients and over 50% of patients have 
moderate to a high level of fatigue4. Fatigue was associated with disability and reduced 
quality of life. Patients consider fatigue more difficult to manage than pain and a major 
reason for disability3. Consequently, fatigue was included as a major outcome domain of RA 
in 2007 by Outcome Measure for Rheumatology (OMERACT)5. However, there is no 
recommendation on the best instrument for assessing fatigue and no approved treatment 
for fatigue in RA6. 
 
The precise biologic mechanism that leads to fatigue in RA remains unknown but it is likely 
to be multi-factorial involving complex pathways7. Inflammation has been implicated in the 
pathobiology of fatigue since it is a common symptom in many chronic inflammatory 
diseases8. Therefore, reducing inflammation may reduce fatigue. However, the effect of 
conventional synthetic (cs) Disease Modifying Anti-Rheumatic Drugs (DMARDs) on fatigue is 
unknown since fatigue is rarely assessed in randomised control trials of csDMARDs. With the 
inclusion of fatigue as a major outcome domain by OMERACT, randomised control trials of 
biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have assessed 
changes in fatigue before and after treatment. 
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Effect of bDMARDs on fatigue 
In 2016, a Cochrane systematic review assessed the effect of bDMARDs in RA was 
published9. This systematic review included 32 randomised control trials or pooled analyses 
of clinical trials of bDMARDs in RA. Twenty studies of anti-TNF agents and twelve 12 non-
anti-TNF biologic agents including abatacept, rituximab,  tocilizumab and canakinumab. In 
total, these studies assessed almost 15,000 patients. Although fatigue has been a core 
outcome domain for RA since 2007, in the absence of a recommended outcome measure 
for assessing fatigue, different instruments had been used in these studies, which included 
the Functional Assessment of Chronic Illness Therapy Fatigue Domain (FACIT-F), Short Form-
36 Vitality Domain (SF-36 VT), visual analogue scale (VAS) and the Numerical Rating Scale 
NRS (0 to 10). SF-36 VT and FACIT-F were the most commonly used outcome measure. SF-36 
is a validated outcome measure for health-related quality of life. It consists of eight 
domains. Four domains are physical and four are mental. The four physical domains are 
physical functioning, role physical, bodily pain and general health. The four mental domains 
are mental health, vitality, role emotional and social functioning. Many studies used the SF-
36 VT score as an inverse measure of fatigue. The Functional Assessment of Chronic Illness 
Therapy is also a health-related quality of life instrument, one of its domains is fatigue. 
FACIT-F score ranges between 0-52 with higher indicates less fatigue. In the Cochrane 
review, changes in fatigue scores were assessed by standardised mean difference so that 
different instruments can be pooled for meta-analysis. Standardised mean differences were 
back transformed into changes in SF-36 VT and FACIT-F. The minimal clinical important 
difference (MCID) for SF-36 VT is 5 points and for FACIF-F is between 3 to 4 points.  
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The Cochrane review concluded that bDMARDs had a moderate effect on reducing fatigue 
with a standardised mean difference of −0.43 (95% CI −0.49 to −0.38), which was statistically 
significant (p < 0.00001). This equates to a difference of 6.45 units (95% CI 5.70 to 7.35) of 
FACIT-F score (range 0-52) or 7.65 units (95% CI 6.76 to 8.72) of SF-36 VT. The number 
needed to treat was 5. In a sub-analysis, categorising bDMARDs into 2 groups: anti-TNF 
agents and non-TNF bDMARDs found similar effects on fatigue. 
  
Anti-TNF bDMARDs included 19 studies with 8946 participants. The standardized mean 
difference between intervention and control groups were −0.42 (P < 0.00001). This 
equates to a difference of 6.3 units of FACIT-F score or 7.5 units of SF-36 vitality. A 
sensitivity analysis found that studies in early RA reported larger effects on fatigue. 
 
For non-TNF bDMARDs, 5682 patients from 11 studies were included in the Cochrane 
review. Non-TNF bDMARDs reduced fatigue with an effect size similar to anti-TNF 
bDMARDs. The standardized mean difference was −0.46 (P < 0.00001). This equates to 6.9 
units of FACIT-F score or 8.19 units of SF-36 VT. 
 
Since the publication of this Cochrane review, an anti-IL-6 receptor monoclonal antibody, 
Sarilumab, and two Janus Kinase Inhibitors (JAKi), Tofacitinib and Baricitinib have been 
approved for the treatment of RA.  
 
Sarilumab 
Sarilumab was approved by the Food and Drug Administration and European Medicine 
Agency for the treatment of RA in 2017. It is a human anti-IL6 receptor monoclonal 
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antibodies similar to Tocilizumab. Fatigue has been assessed in phase 3 clinical trials of 
Sarilumab. 
 
Mobility was a phase III randomized controlled trial in patients with RA who had an 
inadequate response to methotrexate10. Patients were randomised to either placebo or 
subcutaneous Sarilumab 150 or 200 mg fortnightly plus stable doses of methotrexate. 
Changes in FACIT-F score at week 24 in the placebo group was 5.8 ± 0.5 compared with 8.6 ± 
0.5 and  9.2 ± 0.5 in the Sarilumab 150 mg and 200 mg (Table 1). These differences were 
statistically significant. Similarly, the SF-VT reduction was statistically significantly higher in 
the Sarilumab 150 mg (13.9 ± 1.1) and 200 mg groups (18.0 ± 1.0) compared with 9.8 ± 1.2 
in the placebo group. In the 150mg group, 15.6% of patients achieved MCID (defined as > 4 
for FACIT-F and > 5 for VT) for  in both FACIT-F and SF-36 VT scores whilst in the 200mg 
group 21.8% and 23.6% achieved MCID in FACIT-F and SF-36 VT scores respectively. The 
number needed to treat for achieving MCID in fatigue was 6 for 150 mg and 4-5 for 200mg 
groups. 
 
Target was a phase III randomized controlled trial similar to MOBILITY except in patients 
with RA who had an inadequate response to bDMARDs11. Change in FACIT-F score at week 
24 in the placebo group was 6.8 ± 0.9 compared with 9.9 ± 0.8 and 10.1 ± 0.8 in the 
Sarilumab 150 mg and 200 mg respectively. These differences were statistically significant. 
Similarly, the SF-VT reduction was statistically significantly higher in the Sarilumab 150 mg 
(14.5 ± 1.6) and 200 mg groups (16.6 ± 1.5) compared with 9.2 ± 0.8 in the placebo group. In 
the 150mg Sarilumab group, 16.6% of patients achieved MCID in FACIT-F and 13.8% SF-36 
VT whilst in the 200mg group 16.8% and 17.8% achieved MCID in FACIT-F and SF-36 VT 
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scores respectively. The number needed to treat was 6-7 for 150 mg and 6 for 200mg 
groups. 
 
In Monarch, a head-to-head double-blind, double-dummy placebo-control trial compared 
the efficacy of 200mg Sarilumab versus Adalimumab monotherapy12. Efficacy as assessed by 
disease activity score 28 and American College of Rheumatology Response Criteria was 
statistically significantly higher with Sarilumab. However, changes in FACIT-F (10.18+0.7 vs 
8.4+0.71) and SF-36 VT (17.95+1.42 vs 14.39+1.43) were numerically higher in the Sarilumab 
group but the difference versus Adalimumab was not statistically significant. 
 
Table 1: Changes in FACIT-F and SF-36 VT scores in phase III trials of Sarilumab 
 Comparison Group Sarilumab 150mg Sarliumab 200mg 
 FACIT-F SF-36 VT FACIT-F SF-36 VT FACIT-F SF-36 VT 
Mobility 5.8±0.5 9.8±1.2 8.6±0.5 13.9±1.1 9.2±0.5 18.0±1.0 
Target 6.8±0.9 9.2±1.7 9.9±0.8 14.5±1.6 10.1±0.8 16.6±1.5 
Monarch 
(Adalimumab) 
8.4+0.71 14.39+1.43 NA NA 10.18+0.7 17.95+1.42 
FACIT-F: Functional Assessment of Chronic Illness Therapy Fatigue Domain; SF-36 VT: Short 
Form-36 Vitality Domain, NA: not applicable 
 
Janus Kinase Inhibitors 
Janus kinase (JAK) are intracellular molecules which are important for signalling of many 
cytokines13. Oral JAKi have been developed for the treatment of RA. Currently, two JAKi, 
Tofacitinib and Baricitinib, are licensed for the treatment of RA. They are categorised as 
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targeted synthetic DMARDs (tsDMARDs) to differentiate them from bDMARDs and 
csDMARDs. 
 
Tofacitinib 
Tofacitinib is a selective JAK1 and JAK3 inhibitor13. The effect of Tofacitinib on fatigue has 
been reported in 5 phase III clinical trials (Table 2). In these studies, Tofacitinib 5 and 10mg 
bid were evaluated, however, only 5mg bid has been approved for the treatment of RA. 
These clinical trials included patients with inadequate response to methotrexate (Oral 
Standard)14, csDMARDs (Oral Sync)15 or bDMARDs (Oral Step)16 as well as patients with early 
arthritis (Oral Start)17 and used as monotherapy (Oral Solo)18. In Oral Standard, Oral Sync 
Oral Step and Oral Solo, the effect of tofacitinib were compared with placebo. In Oral Start, 
comparisons were made against active treatment by methotrexate. Table 2 shows the effect 
of treatment on FACIT-F on SF-36 VT at week 12 which is the primary endpoint of these 
trials. 
 
 
Table 2: Changes in FACIT-F and SF-36 VT scores at week 12 in phase III trials of Tofacitinib 
 Comparison Group Tofacitinib 5mg Tofacitinib 10mg 
 FACIT-F SF-36 VT FACIT-F SF-36 VT FACIT-F SF-36 VT 
Oral Sync 2.1+0.6 2.6 ± 0.7 5.8+0.5 6.3±0.5 6.9+0.5 6.5±0.5 
ORAL Step 1.11+1.04  2.20+0.90  6.27+1.01  6.40+0.89  4.57+1.03 6.71+0.91 
ORAL Solo 2.84+0.82  2.03+0.81  6.70+0.56  6.56+0.55  8.01+0.58 8.49+0.57 
ORAL Standard 1.57+0.79 2.21+0.82 5.85+0.59  4.97+0.61  6.88+0.59 7.21+0.61 
 9 
ORAL Start 
(Methotrexate) 
5.33+0.67 5.06+0.70 8.19+0.48  8.20+0.50 8.72+0.46 8.84+0.48 
FACIT-F: Functional Assessment of Chronic Illness Therapy Fatigue Domain; SF-36 VT: Short 
Form-36 Vitality Domain 
 
Tofacitinib statistically significantly reduced fatigue when compared with placebo in Oral 
Standard, Sync, Step and Solo. In Oral Start, improvement in fatigue was statistically 
significantly superior to methotrexate. 
 
Baricitinib 
Baricitinib is a JAK-1 and JAK-2 selective inhibitor13. Changes in fatigue in four randomised 
placebo control trials have been reported.  These trials were conducted in RA patients with 
inadequate response to methotrexate (RA-Beam), csDMARDs (RA-Build) and bDMARDs (RA-
Beacon) as well as patients with early RA (RA-Begin). 
 
In RA-BEAM, patients with inadequate response to methotrexate were randomised to 
receive placebo, Baricitinib 4 mg once daily, or fortnightly Adalimumab 40 mg, in 
addition to their existing csDMARDs19. The primary endpoint was at week 12. Changes in 
FACIT-F score at week 12 was statistically significantly higher in Baricitinib and Adalimumab 
treated patients when compared with placebo. Percentages of patients who achieved at 
MCID improvement were also higher in these groups (Table 3).  
 
In RA Build, patients with inadequate response to csDMARDs20, were randomised to receive 
either placebo or Baricitinib 2 or 4mg daily. Improvement in fatigue as measured by FACIT-F 
score was statistically significantly higher at week 24 for Baricitinib 4 mg when compared to 
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placebo but not at week 12. Changes in FACIT-F in the 2mg group were numerically higher 
than placebo but were not statistically significant. Percentages of the patient who achieved 
MCID in FACIT-F score was 43%, 59% and 60% at week 24 (p=0.001 for both Baricitinib 
groups vs placebo not statistically significant at week 12 which was 59%, 63% and 65% for 
placebo, Baricitinib 2 mg and Baricitinib 4 mg, respectively.  
 
RA-Beacon is a phase III study of Baricitinib in patients with RA and an inadequate response 
to bDMARDs21. Patients were randomised to receive either placebo or Baricitinib 2 or 4mg 
daily. Improvement in fatigue as measured by FACIT-F score was statistically significantly 
higher in Baricitinib 2mg and 4mg at week 12 when compared with placebo. Percentages of 
patients who achieved at least MCID improvement were also statistically significantly higher 
(Table 3). 
 
RA-Early is a double-blind, phase III study of Baricitinib as monotherapy or combined with 
methotrexate versus methotrexate monotherapy in patients with active early RA22. Changes 
in FACIT-F score after 24 weeks was 8.9 (95% confidence interval 7.6 to 10.1) in the 
methotrexate group, 13.3 (95% confidence interval 11.8, 14.7) in Baricitinib monotherapy 
group and 12.2 (95% confidence interval 11.0, 13.5) in the methotrexate plus Baricitinib 
group. The differences between the Baricitinib groups versus the methotrexate group were 
statistically significant. Percentages of patients achieving MCID (defined as > 3.56 for FACIT-
F and > 5 for VT)  at week 24 were was 65%, 75%, and 71% for methotrexate, Baricitinib 
monotherapy, and Baricitinib plus methotrexate, respectively.  
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Table 3: Percentage of Patients with improvement in FACIT-F score more than the 
minimum clinically important difference of 3.56 at week 12 in phase III trials of Baricitinib 
 Comparison 
Group 
Baricitinib 2mg Baricitinib 4mg 
 FACIT-F FACIT-F FACIT-F 
RA-Beam 59% 
 
NA 66%* 
RA-Build 59% 63% 65% 
RA-Beacon 48% 
 
64%* 63%* 
 Methotrexate Baricitinib 4mg 
monotherapy 
Baricitinib 4mg plus 
methotrexate 
RA-Early 65% 75% 71% 
FACIT-F: Functional Assessment of Chronic Illness Therapy Fatigue Domain; NA: Not 
applicable 
 
Discussion 
The Cochrane review in 2016 concluded that bDMARDs have a moderate effect in reducing 
fatigue in patients with RA. Since then, data from trials of Sarilumab on fatigue is consistent 
with this conclusion and the effect size of Sarilumab was similar to other bDMARDs 
including tocilizumab. Clinical trials of the tsDMARDs, Tofacitinib and Baricitinib, also 
suggested they may reduce fatigue. However, it is difficult to compare their effects with 
bDMARDs as the primary endpoint were at 12 weeks rather than 24 weeks. Given the effect 
size of treatment was similar, this would suggest bDMARDs and tsDMARDs improve fatigue 
by reducing disease activity.  
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One should be mindfulness of the fact that these studies were designed to examine clinical 
the efficacy of bDMARDs and tsDMARDs in RA and fatigue was only assessed as a secondary 
endpoint rather than the primary endpoint. It is unclear whether improvement in fatigue is 
sustained with long-term therapy. Furthermore, analysis of fatigue in these studies did not 
adjust for possible confounding factors such as changes in pain, haemoglobin or mood. In 
addition, most of the studies compared bDMARDs or tsDMARDs in combination with 
methotrexate, their true effect size on fatigue is less certain. 
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